Supplementary material: estimate of trips avoided, and distribution of associated savings.

Table VI. Estimate of trips avoided and associated time due to the pilot experience

Total avoided trips (km)*	93,305
Avoided trips from outside of Santander (km)	89,073
Time associated with total avoided trips (hours)	1,374

^{*} Note: informed deliveries in CPh located less than 1 km from the hospital were not taken into account

Table VII. Distribution of savings associated with trips avoided, by prescription type

Prescription type	Savings associated with trips avoided		Avoided labor productivity losses	
	€	%	€	%
Hospital diagnosis	5,132	57.6%	8,385	58.2%
Hospital use	3,207	36.0%	4,986	34.6%
Medication used in special situations	568	6.4%	1,031	7.2%
Total	8,907	100%	14,402	100%

Table VIII. Distribution of savings associated with trips avoided, by ATC1 code

ATC1 Code	Savings associated with trips avoided		Avoided labor productivity losses	
	€	%	€	%
A - Alimentary tract and metabolism	230	2.6%	343	2.4%
B - Blood and blood-forming organs	996	11.2%	1,527	10.6%
C - Cardiovascular system	581	6.5%	1,034	7.2%
D - Dermatological	28	0.3%	47	0.3%
G - Genitourinary system and sex hormones	23	0.3%	44	0.3%
H - Systemic hormonal preparations, excluding sex hormones and insulins	220	2.5%	324	2.3%
J – Anti-infectives for systemic use	749	8.4%	1,208	8.4%
L - Antineoplastic and immunomodulating agents	5,596	62.8%	9,081	63.1%
N - Nervous system	283	3.2%	470	3.3%
R - Respiratory system	126	1.4%	197	1.4%
S - Sensory organs	67	0.8%	117	0.8%
V - Miscellaneous	7	0.1%	10	0.1%
Total	8,907	100%	14,402	100%

Table IX. Distribution of savings associated with trips avoided, by route of administration

Route of administration	Savings associated with trips avoided		Avoided labor productivity losses	
	€	%	€	%
Oral	3,941	44%	6,255	43%
Intravenous/subcutaneous	1,078	12%	1,670	12%
Subcutaneous	3,378	38%	5,654	39%
Other forms	159	2%	263	2%
Other combinations	355	4%	590	4%
Total	8,907	100%	14,402	100%